UCB has opened a new manufacturing facility in Shannon. The new facility will enable the production of Fesoterodin for over-active bladder, which has been developed by Schwarz Pharma, now part of the UCB Group, and is licensed exclusively to Pfizer. Construction and other site upgrades at the facility will be completed by the end of this year and the plant will be in operation in 1Q2008.
   
Dr. Roch Doliveux, chief executive officer and chairman of the executive committee of UCB, said, “This new facility will enable the production of an important new drug here. With worldwide investments in R&D and the full integration of Schwarz Pharma, UCB is actively building the next generation biopharma leader. UCB today is large enough to advance an especially rich pipeline and to launch our new products to specialists first. The recent launches of Neupro and Xyzal in the U.S. demonstrate the power to execute our projects”